Pharmacogenomics steps toward personalized medicine (Q56446183)

https://api.crossref.org/works/10.2217%2F17410541.2.4.325

The Sequence of the Human Genome

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17410541.2.4.325

Pharmacogenetics of CYP2C9 and interindividual variability in anticoagulant response to warfarin

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17410541.2.4.325

Common VKORC1 and GGCX polymorphisms associated with warfarin dose

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17410541.2.4.325

Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17410541.2.4.325

Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17410541.2.4.325

Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17410541.2.4.325

Readmissions and adverse drug reactions in internal medicine: the economic impact.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17410541.2.4.325

Lack of awareness of community-acquired adverse drug reactions upon hospital admission : dimensions and consequences of a dilemma.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17410541.2.4.325

Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17410541.2.4.325

Priorities and standards in pharmacogenetic research

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17410541.2.4.325

Pharmacogenetics and rheumatology: Molecular mechanisms contributing to variability in drug response

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17410541.2.4.325

Inheritance and drug response

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17410541.2.4.325

Pharmacogenomics: bench to bedside

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17410541.2.4.325

Pharmacogenetics - five decades of therapeutic lessons from genetic diversity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17410541.2.4.325

Pharmacogenomics: the inherited basis for interindividual differences in drug response

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17410541.2.4.325

Pharmacogenomics--drug disposition, drug targets, and side effects

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17410541.2.4.325

Pharmacogenetics goes genomic

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17410541.2.4.325

Molecular diagnostics as a predictive tool: genetics of drug efficacy and toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17410541.2.4.325

Advances in pharmacogenomics and individualized drug therapy: exciting challenges that lie ahead

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17410541.2.4.325

The thiopurine S-methyltransferase gene locus -- implications for clinical pharmacogenomics

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17410541.2.4.325

Pharmacogenetic testing for drug metabolizing enzymes: is it happening in practice?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17410541.2.4.325

Preventing Toxicity With a Gene Test

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17410541.2.4.325

A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17410541.2.4.325

Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17410541.2.4.325

Association of Vitamin K epoxide reductase complex 1 (VKORC1) variants with warfarin dose in a Hong Kong Chinese patient population

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17410541.2.4.325

Association of pharmacokinetic (CYP2C9) and pharmacodynamic (factors II, VII, IX, and X; proteins S and C; and gamma-glutamyl carboxylase) gene variants with warfarin sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17410541.2.4.325

Effects of cytochrome P450 2C9 polymorphisms on phenprocoumon anticoagulation status

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17410541.2.4.325

CYP2C9 allelic variants: ethnic distribution and functional significance

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17410541.2.4.325

Relative impact of covariates in prescribing warfarin according to CYP2C9 genotype

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17410541.2.4.325

Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17410541.2.4.325

Identification of a null allele of CYP2C9 in an African-American exhibiting toxicity to phenytoin

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17410541.2.4.325

Genetic predictors of the maximum doses patients receive during clinical use of the anti-epileptic drugs carbamazepine and phenytoin

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17410541.2.4.325

Codeine intoxication associated with ultrarapid CYP2D6 metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17410541.2.4.325

Adverse drug reactions to oxycodone and hydrocodone in CYP2D6 ultrarapid metabolizers

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17410541.2.4.325

Genes and the response to drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17410541.2.4.325

Targeting targeted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17410541.2.4.325

21 January 2018

Targeted cancer therapy

1 reference

https://api.crossref.org/works/10.2217%2F17410541.2.4.325

Identification and characterization of novel sequence variations in the cytochrome P4502D6 (CYP2D6) gene in African Americans

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17410541.2.4.325

Mechanisms of clinical resistance to small molecule tyrosine kinase inhibitors targeting oncogenic tyrosine kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17410541.2.4.325

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17410541.2.4.325

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17410541.2.4.325

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17410541.2.4.325

Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17410541.2.4.325

Cancer. A bull's eye for targeted lung cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17410541.2.4.325

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17410541.2.4.325

Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17410541.2.4.325

Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line H3255.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17410541.2.4.325

Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17410541.2.4.325

ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17410541.2.4.325

Spotlight on gefitinib in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17410541.2.4.325

Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17410541.2.4.325

Practical management of patients with non-small-cell lung cancer treated with gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17410541.2.4.325

Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17410541.2.4.325

New studies look beyond EGFR mutations for clues to sensitivity to erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17410541.2.4.325

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17410541.2.4.325

Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17410541.2.4.325

Gefitinib versus cetuximab in lung cancer: round one.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17410541.2.4.325

Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17410541.2.4.325

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17410541.2.4.325

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17410541.2.4.325

Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17410541.2.4.325

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17410541.2.4.325

Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17410541.2.4.325

EGFR mutation conferring primary resistance to gefitinib in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17410541.2.4.325

Epithelial membrane protein-1 is a biomarker of gefitinib resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17410541.2.4.325

Cancer pharmacogenomics: powerful tools in cancer chemotherapy and drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17410541.2.4.325

Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17410541.2.4.325

Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17410541.2.4.325

A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17410541.2.4.325

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17410541.2.4.325

Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17410541.2.4.325

Overriding imatinib resistance with a novel ABL kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17410541.2.4.325

Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17410541.2.4.325

Imatinib mesylate--a new oral targeted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17410541.2.4.325

Evolving ways that drug therapy is individualized.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17410541.2.4.325

Personalized drug therapy; the genome, the chip and the physician

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17410541.2.4.325

Welcome to the genomic era.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17410541.2.4.325

Accurate multiplex polony sequencing of an evolved bacterial genome

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17410541.2.4.325

Moving towards individualized medicine with pharmacogenomics

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17410541.2.4.325

Pharmacogenomics and "individualized drug therapy": high expectations and disappointing achievements

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17410541.2.4.325

Education: Teaching pharmacogenomics to prepare future physicians and researchers for personalized medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17410541.2.4.325

Pharmacogenomics education: International Society of Pharmacogenomics recommendations for medical, pharmaceutical, and health schools deans of education.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17410541.2.4.325

21 January 2018

An individual approach

1 reference

https://api.crossref.org/works/10.2217%2F17410541.2.4.325